Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902018 · ClinicalTrials.gov registry record · Phase 2
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00902018 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants.
The verdict
NCT00902018, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to further evaluate the effects that eltrombopag (and romiplostim) have on platelets in subjects with chronic ITP. Eltrombopag is approved by the Food and Drug Administration (FDA) for the treatment of low platelets in patients with chronic ITP. It is being further studied by GlaxoSmithKline (now Novartis) in other conditions associated with low platelets. This research study is being done because eltrombopag has been shown to increase platelet counts in a different way than other therapies for ITP. The investigators want to further study how eltrombopag and romiplostim affect subjects and their platelets to determine how the study drug should best be used in ITP treatment.
Interventions
- DRUG Eltrombopag
- DRUG Romiplostim
- OTHER healthy controls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-01 |
| Est. Completion | 2015-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00902018
The ClinicalTrials.gov registry entry for NCT00902018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Eltrombopag is the first listed.
NCT00902018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00902018 about?
NCT00902018 is a clinical study titled "Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)". The purpose of this study is to further evaluate the effects that eltrombopag (and romiplostim) have on platelets in subjects with chronic ITP. Eltrombopag is approved by the Food and Drug Administration (FDA) for the treatment of low platelets in patients with chronic ITP. It is being further studi...
What is the current status of trial NCT00902018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2009-01. Estimated completion is 2015-09-07.
What interventions are being tested in trial NCT00902018?
The interventions under investigation include: Eltrombopag (DRUG), Romiplostim (DRUG), healthy controls (OTHER).
Who is sponsoring clinical trial NCT00902018?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.